Research programme: age-related disease therapeutics - Tartis
Latest Information Update: 22 Jul 2016
At a glance
- Originator Tartis
- Class Antineoplastics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Unspecified
Most Recent Events
- 22 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)
- 22 Jul 2016 Preclinical trials in Undefined indication (Age-related diseases) in USA (unspecified route)